Drug Profile
Ethyl eicosapentaenoic acid - Mochida Pharmaceutical
Alternative Names: eicosapentaenoic acid ethyl ester; EPA-E; Epadel; ethyl icosapentaenoate; ethyl icosapentate; MND 2119; MND-21Latest Information Update: 05 Apr 2022
Price :
$50
*
At a glance
- Originator Mochida Pharmaceutical
- Developer Mochida Pharmaceutical; Sumitomo Pharma
- Class Antidementias; Antidepressants; Antihyperlipidaemics; Antineoplastics; Antiplatelets; Antivirals; Eicosanoids; Esters; Omega 3 fatty acids; Reactive oxygen species; Small molecules; Vascular disorder therapies
- Mechanism of Action Diacylglycerol O acyltransferase inhibitors; Phospholipase A2 inhibitors; Platelet aggregation inhibitors; Triglyceride modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Atherosclerosis; Hyperlipidaemia
- Phase III Hypertriglyceridaemia
- Phase II Alzheimer's disease